加拿大MedMira公司被批准进行新的梅毒测试的临床试验,因为感染率猛增。 Canadian firm MedMira gets approval for clinical trials of new syphilis test as infection rates soar.

加拿大MedMira公司已经获得加拿大卫生部的批准,开始临床试验,以进行Multiplo 完整的梅毒抗体测试,该测试能够检测到活跃和非活跃的梅毒感染。 Canadian company MedMira Inc. has received approval from Health Canada to start clinical trials for its Multiplo® Complete Syphilis Antibody Test, which can detect both active and non-active syphilis infections. 审判将由圣迈克尔医院的REACH Nexus领导,由加拿大卫生研究所和加拿大土著服务局资助。 The trials will be led by REACH Nexus at St. Michael's Hospital, funded by the Canadian Institute of Health Research and Indigenous Services Canada. 这是因为自2018年以来,加拿大梅毒发病率上升了109%,突出表明需要有准确和成本效益高的检测方法。 This comes as syphilis rates in Canada have risen by 109% since 2018, highlighting the need for accurate and cost-effective testing options.